MX9701859A - Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos. - Google Patents
Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.Info
- Publication number
- MX9701859A MX9701859A MX9701859A MX9701859A MX9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A MX 9701859 A MX9701859 A MX 9701859A
- Authority
- MX
- Mexico
- Prior art keywords
- colon carcinoma
- monoclonal antibodies
- associated antigens
- human colon
- antibodies against
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen anticuerpos monoclonales, en particular 233.28 y 33.1 y anticuerpos quiméricos, en particular Chi # 1 quimérico raton/humano específico para antígenos de glicoproteína de antígenos asociados con carcinoma de colon, los cuales son inmunogénicos en los seres humanos. Tales anticuerpos, y los fragmentos y derivados de los mismo, son utiles en inmunodiagnosis e inmunoterapia de cáncer de colon, de pecho y de ovario humanos, y para la purificacion de antígenos, los cuales pueden servir como agentes inmunoterapéuticos. Se describen también métodos para detectar el antígeno asociado al carcinoma de colon en una muestra, y los métodos para tratar sujetos que tienen carcinomas de colon, de pecho y de ovario.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/304,524 US5688657A (en) | 1988-03-31 | 1994-09-12 | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9701859A true MX9701859A (es) | 1998-07-31 |
Family
ID=23176896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9701859A MX9701859A (es) | 1994-09-12 | 1997-03-12 | Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5688657A (es) |
EP (1) | EP0777690A4 (es) |
JP (1) | JPH10505749A (es) |
KR (1) | KR970706307A (es) |
AU (1) | AU3587095A (es) |
CA (1) | CA2199740A1 (es) |
IL (1) | IL115232A0 (es) |
MX (1) | MX9701859A (es) |
WO (1) | WO1996008514A1 (es) |
ZA (1) | ZA957634B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
EP1291657A3 (en) | 1996-01-30 | 2003-08-27 | Exact Sciences Corporation | Methods for detecting colon cancer from stool samples |
US6247995B1 (en) | 1996-02-06 | 2001-06-19 | Bruce Bryan | Bioluminescent novelty items |
US7318921B2 (en) * | 1996-05-15 | 2008-01-15 | Altarex Medical Corp. | Therapeutic compositions that alter the immune response |
US7361346B1 (en) * | 1996-05-15 | 2008-04-22 | Altarex Corp. | Therapeutic compositions that produce an immune response |
US20080220012A1 (en) * | 1996-05-15 | 2008-09-11 | Ragupathy Madiyalakan | Therapeutic Compositions that alter the immune response |
US8038994B2 (en) * | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
CA2253602A1 (en) * | 1996-05-15 | 1997-11-20 | Altarex Corp. | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
US20060159688A1 (en) * | 1996-05-15 | 2006-07-20 | Ragupathy Madiyalakan | Method for diagnosing efficacy of xenotypic antibody therapy |
US6416960B1 (en) | 1996-08-08 | 2002-07-09 | Prolume, Ltd. | Detection and visualization of neoplastic tissues and other tissues |
US6300077B1 (en) | 1996-08-14 | 2001-10-09 | Exact Sciences Corporation | Methods for the detection of nucleic acids |
US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6203993B1 (en) | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
JP3795533B2 (ja) | 1996-12-12 | 2006-07-12 | プロルーム・リミテツド | 感染性物質を検出及び同定するための方法及び装置 |
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
CA2309990A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
US20050260177A1 (en) * | 1998-06-05 | 2005-11-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
JP2002525031A (ja) * | 1998-08-04 | 2002-08-13 | ダイアデクスアス・インコーポレーテッド | 大腸癌の診断、監視、病期決定、画像処理及び治療の新規方法 |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6280947B1 (en) | 1999-08-11 | 2001-08-28 | Exact Sciences Corporation | Methods for detecting nucleotide insertion or deletion using primer extension |
NZ513838A (en) * | 1999-03-11 | 2003-02-28 | Smithkline Beecham Biolog S | Novel compounds |
US6693176B1 (en) * | 1999-07-23 | 2004-02-17 | University Of Massachusetts | Antitumor antibodies, proteins, and uses thereof |
US20020199218A1 (en) * | 1999-08-19 | 2002-12-26 | Daphne Goring | Proline-rich extensin-like receptor kinases |
CA2410895A1 (en) | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
US6801270B2 (en) * | 2000-06-26 | 2004-10-05 | Reveo, Inc. | Backlight for a liquid crystal display having high light-recycling efficiency |
US7491801B2 (en) * | 2000-09-01 | 2009-02-17 | International Bioimmune Systems, Inc. | Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
CA2364983A1 (en) * | 2000-12-13 | 2002-06-13 | John R. Coleman | Nucleic acid molecules and polypeptides for catabolism of abscisic acid |
US7597895B2 (en) * | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US7556807B2 (en) | 2001-02-20 | 2009-07-07 | Kane Biotech, Inc. | Signal peptides, nucleic acid molecules and methods for treatment of caries |
ATE495751T1 (de) | 2001-03-15 | 2011-02-15 | Neogenix Oncology Inc | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
CA2464239C (en) | 2001-10-23 | 2016-07-12 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
AU2002351374A1 (en) * | 2001-12-11 | 2003-06-23 | Corixa Corporation | Antibodies to treat cancer |
JP2005522483A (ja) * | 2002-04-11 | 2005-07-28 | アルタレックス メディカル コーポレーション | 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用 |
EP1532162B1 (en) | 2002-06-28 | 2013-08-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
EP1529060B1 (de) | 2002-07-22 | 2014-09-10 | Glycotope GmbH | Verfahren zur herstellung eines immunstimulatorischen muzins (muc1) |
LT2891666T (lt) | 2002-10-16 | 2017-10-10 | Purdue Pharma L.P. | Antikūnai, kurie prisiriša su ląstelėmis susijusį ca 125/o722p ir jų naudojimo būdas |
US20040115204A1 (en) | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
WO2005021594A2 (en) * | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
WO2006004950A2 (en) * | 2004-06-30 | 2006-01-12 | International Bioimmune Systems, Inc. | Humanized monoclonal antibody 31.1 as an anticancer agent |
WO2006047787A2 (en) | 2004-10-27 | 2006-05-04 | Exact Sciences Corporation | Method for monitoring disease progression or recurrence |
WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
MX2009011667A (es) * | 2007-05-07 | 2009-11-10 | Hoffmann La Roche | Anticuerpos de modificacion de enfermedad cancerosa. |
CA2700197C (en) * | 2007-11-08 | 2020-09-08 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
ES2670588T3 (es) | 2009-06-26 | 2018-05-31 | Soricimed Biopharma Inc. | Péptidos derivados de soricidina y métodos para la detección de cánceres TRPV-6 y administración de fármacos |
CA2803391C (en) | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
WO2015123654A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
-
1994
- 1994-09-12 US US08/304,524 patent/US5688657A/en not_active Ceased
-
1995
- 1995-09-11 IL IL11523295A patent/IL115232A0/xx unknown
- 1995-09-12 EP EP95933081A patent/EP0777690A4/en not_active Withdrawn
- 1995-09-12 ZA ZA957634A patent/ZA957634B/xx unknown
- 1995-09-12 WO PCT/US1995/011554 patent/WO1996008514A1/en active Search and Examination
- 1995-09-12 AU AU35870/95A patent/AU3587095A/en not_active Abandoned
- 1995-09-12 CA CA002199740A patent/CA2199740A1/en not_active Abandoned
- 1995-09-12 JP JP8510288A patent/JPH10505749A/ja not_active Ceased
- 1995-09-12 KR KR1019970701636A patent/KR970706307A/ko not_active Application Discontinuation
-
1997
- 1997-03-12 MX MX9701859A patent/MX9701859A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US5688657A (en) | 1997-11-18 |
AU3587095A (en) | 1996-03-29 |
KR970706307A (ko) | 1997-11-03 |
JPH10505749A (ja) | 1998-06-09 |
EP0777690A1 (en) | 1997-06-11 |
ZA957634B (en) | 1996-05-27 |
IL115232A0 (en) | 1995-12-31 |
EP0777690A4 (en) | 2000-07-05 |
WO1996008514A1 (en) | 1996-03-21 |
CA2199740A1 (en) | 1996-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9701859A (es) | Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos. | |
MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
NO175944C (no) | Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse | |
WO2003099196A3 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
EP0823913A4 (en) | SYNTHESIS OF THE BREAST TUMOR ASSOCIATED ANTIQUE DEFINED BY THE MONOCLONAL ANTIBODY MBR1 AND ITS USE | |
SG96535A1 (en) | Pharmaceutical composition for the treatment or prevention of a malignant tumor | |
KR910700077A (ko) | 인체 종양과 관련된 신규 항원에 대한 신규한 모노클로날 항체 | |
ZA945364B (en) | Antibodies specific for human prostate glandular kallikrein | |
IL139700A0 (en) | Immunotherapeutic composition and method for the treatment of prostate cancer | |
IL148113A0 (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
NZ210867A (en) | Tumour-specific monoclonal antibodies, production thereof and use | |
ATE128986T1 (de) | Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen. | |
EP1411962A4 (en) | MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER | |
KR900701318A (ko) | 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체 | |
EP0420848A4 (en) | Carcinoma-associated antigens, and antibodies which recognize these antigens | |
ATE292681T1 (de) | E-cadherin-mutationen als grundlage zur diagnostik und therapie humaner maligner tumoren | |
ZA927785B (en) | Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof | |
GR3020387T3 (en) | Ctaa 28a32, the antigen recognized by mca 28a32 | |
ZA884777B (en) | Antigen recognized by mca 16 88 | |
WO1999043815A3 (en) | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof | |
GR890100333A (en) | Antihuman antigen antibodies | |
DE69229829D1 (de) | Tumorspezifischer monoklonaler antikörper 81av78 | |
ES2088820A1 (es) | Anticuerpos monoclonales antineumolisina. |